The -Lactam antibiotics represent the most successful dug class for treatment of bacterial infections. Resistance to them, importantly via production of -lactamases, which collectively are able to hydrolyse all classes of -lactams, threatens their continued widespread use. Bicyclic boronates show potential as broad spectrum inhibitors of the mechanistically distinct serine-and metallo-serine (SBL) and metallo (MBL) -lactamase families. Together with reported studies on the structural basis of bicyclic boronate inhibition of class A, B and D -lactamases, biophysical studies including crystallographic analysis of a bicyclic boronate in complex with the clinically important class C AmpC SBL from Pseudomonas aeruginosa supports the proposal bicyclic boronates mimic tetrahedral intermediates common to SBL and MBL catalysis. Microbiological studies on the clinical coverage (in combination with meropenem) and induction of -lactamases by bicyclic boronates further support the promise of such compounds as broad spectrum -lactamase inhibitors.
Introduction
The -Lactam antibiotics represent the most successful dug class for treatment of bacterial infections 1 . Resistance mechanisms, particularly the production of -lactamases, which collectively are able to hydrolyse all the classes of -lactam antibiotic, endanger their continued widespread use 2 ( Figure 1A ). Success has been had in the treatment of bacterial infections exhibiting resistance by some serine--lactamases (SBLs), particularly Ambler class A enzymes, via co-adminstration of a penicillin with a -lactam based SBL inhibitor, i.e. clavulanic acid [3] [4] , sulbactam, 5 or tazobactam 6 . The recent introduction of avibactam, which is active against class A, C, and some class D -lactamases, demonstrates the viability of nonlactam based -lactamase inhibition and is an important step in more broadly combating SBLs 7 .
Acyclic boronic acids have long been known to inhibit nucleophilic enzymes, including SBLs [8] [9] ( Figure 1B) . In co-administration with meropenem the (predominantly) monocyclic boronic acid, vaborbactam ( Figure 1C ), has been introduced for treatment of complicated urinary tract infections (cUTI) 10 . Vaborbactam is relatively potent in inhibiting class A SBLs, including the KPC carbapenemases, but is not active against MBLs and, at least, some clinically relevant SBLs 10 . By contrast with the SBLs, to date there are no clinically useful inhibitors of the metallo--lactamases (MBLs, Ambler class B) 11 , which are structurally and mechanistically distinct from the SBLs and which are structurally heterogeneous (B1-3 MBL subfamilies) 12 ( Figure 1A) . The ability of the MBLs to hydrolyse -lactam based SBL inhibitors prohibits their use against bacteria producing both MBLs and SBLs 12 . The observation that MBLs can bind and hydrolyse avibactam, albeit slowly 13 , as well as SBL-mediated resistance to avibactam suggests that the future use of avibactam will be jeopardised by -lactamases 1314 . Thus the development of dual-action SBL and MBL -lactamase inhibitors is of interest.
We have reported that boronates with a (at least predominantly, in solution) bicyclic scaffold are able to inhibit representatives of all four Ambler classes [15] [16] [17] . These inhibitors are proposed to mimic the tetrahedral intermediates in -lactam hydrolysis common to both SBLs and MBL [15] [16] . We now report a crystal structure of a bicyclic boronate in complex with the clinically important class C AmpC -lactamase from Pseudomonas aeruginosa. Together with reported studies on the structural basis of bicyclic boronate inhibition of class A, B and Dlactamases and other biophysical analyses our results support the proposal that bicyclic boronates mimic the tetrahedral intermediates common to both serine-and metallo--lactamase hydrolysis. Microbiological studies on the clinical coverage (in combination with meropenem) and induction of -lactamases by bicyclic boronates validate the potential of such compounds as broad spectrum -lactamase inhibitors.
Experimental Procedures

Enzyme production
Recombinant VIM-2, with an N-terminal His-tag, was produced using the reported pOPINF construct 18 in E. coli BL21(DE3) pLysS cells using 2TY medium supplemented with 50 g mL -1 ampicillin and 50 g mL -1 chloramphenicol. Cells were grown until an OD600 of 0.6 -0.7 was reached before cooling to 30 °C; expression was induced with isopropyl -D-1thiogalactopyranoside (0.5 mM final concentration). The cells were then incubated for a further four hours at 30 °C. Recombinant AmpC from P. aeruginosa 15 , with an N-terminal His-tag, was produced in E. coli BL21(DE3) cells using auto-induction medium supplemented with 50 g mL -1 ampicillin. Cells were grown for four hours at 37 °C before cooling to 18 °C and continuing growth overnight.
Cells were harvested by centrifugation (10 min, 10000 g), resuspended in 50 mL lysis buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 5 mM imidazole), supplemented with DNAse 
Crystallisation Experiments, X-ray Data Collection and Processing
Crystallisation experiments were set up using a 18 mg mL -1 solution of AmpC in 50 mM HEPES, pH 7.5, 100 mM NaCl supplemented with 10 mM 1. 1 and 2 were prepared as reported 16 . Crystallisation was performed at room temperature using the sitting drop vapour 
Surface Plasmon Resonance
A GE Healthcare Biacore T200 machine was used for all SPR experiments. The temperature was kept at 4 o C to increase stability of the protein on the chip. VIM-2 was 'minimally' 
-Lactamase Induction Experiments
Induction experiments were carried out as described 22 . In brief, cell cultures were grown overnight using nutrient broth and used to inoculate (1:100 dilution) 10 mL nutrient broth cultures. Cultures were incubated for 2 h with shaking at 37 °C before addition of potential inducers and growth for a further 2 h. Cells were pelleted by centrifugation (4000 g, 10 min) and were treated with 100 µL of BugBuster (Ambion). Cell debris was pelleted by centrifugation (13,000g, 5 min). Protein concentrations in the supernatant were determined using a BioRad protein assay reagent concentrate, according to the manufacturer's instructions.
-lactamase activity was determined using an Omega Fluostar (BMG Biotech) using meropenem as substrate.
Antimicrobial Susceptibility Testing
MICs were determined and interpreted for meropenem both alone, and in combination with 2 (10 g/ml), by EUCAST/CLSI guidelines, in line with previously reported data 23 .
Results
To investigate the structural basis of class C -lactamase inhibition by bicyclic boronates we co-crystallised recombinant AmpC from P. aeruginosa in complex with bicyclic boronate 1. Although crystals were only obtained after months, the overall fold of the AmpC- The bicyclic core of 1 binds to AmpC in a remarkably similar conformation / mode to that observed for the class A (CTX-M-15 and L2) and D (OXA-10) SBLs (Figure 2 ), i.e. via formation of a likely anionic tetrahedral species formed via reaction of the active site nucleophilic serine with the boron of 1 to produce a complex mimicking that proposed in -lactamase mediated hydrolysis of bicyclic -lactams [15] [16] 22 . The binding of the aryl carboxylate is similar in all cases, with differences reflecting the different residues involved in binding this substrate element in the different SBL types. A similar binding mode, including with respect to the observation of a tetrahedral boron has also been observed for 1/2 when complexed with PBP5 from Escherichia coli 16 , though note that the tested bicyclic boronates tend to be much weaker PBP inhibitors (and antibiotics) than -lactamase inhibitors [15] [16] Thus, a conserved mode of binding is observed for bicyclic boronates with all three Ambler classes of serine-lactamase and, at least, one penicillin binding protein (PBP-5). Although, there are differences in the active site chemistry of the SBLs and MBLs, crystallographic analyses on the class B1 MBLs BcII and VIM-2 [15] [16] show that the conformation of the biyclic boronate 2 as observed in SBLs (and PBP5) is also maintained in binding to these clinically relevant MBLs 15-16 ( Figure   2 ). aeruginosa in complex with 4,5-disubstituted oxaboroles (4WYY and 4WZ4) 28 , although the aromatic carbocycle is oriented differently in these cases, likely due to the differently positioned carboxylate moiety in these molecules.
An overlay of our
Reaction of an sp 2 boron, or substitution of an sp 3 B-OH, with the nucleophilic serine is necessary to form the crystallographically observed tetrahedral (sp 3 ) complex in the case of the SBLs/PBPs. However, for the MBLs either the sp 2 or sp 3 forms of the inhibitor could be envisaged to bind. To investigate binding of 2 to an MBL in solution, we used surface plasmon resonance (SPR) with the clinically relevant B1 MBL VIM-2. Data were collected at pH 6.5, 7.5, and 8.5 ( Figure 3A and Supplementary Figure S1 ). The affinity of 2 for VIM-2, as measured by the KD, varies by 10 fold with pH, with the lowest KD at pH 6.5 (4.97 nM) and a highest at pH 8.5 (55.3 nM), with the differences principally being due to changes in the association rate (kon). At least in part this may reflect a bias to the sp 2 rather than the sp 3 hybridisation states of the boron of the inhibitor at lower pH 29 , though other factors including potential ring opening/closing of the inhibitor ( Figure 1B ) and the -lactamase protonation state may be relevant, these observations are consistent with the sp 2 form of the inhibitor reacting with the zinc ion activated hydrolytic water / hydroxide at the VIM-2 active site.
Treatment of bacteria with -lactam antibiotics can induce expression of chromosomal genes
for -lactamases, for example AmpC enzymes 30 . This upregulation can arise as a result of signalling due to inhibition of cell wall biosynthesis by -lactam antibiotics 30 . Administration of all clinically used -lactamase inhibitors results in upregulated -lactamase production 2, 31 , hence -lactamase inhibitors that do not induce such an effect may useful in a clinical setting.
We have reported that both 2 and avibactam do not manifest detectable -lactamase induction in S. maltophilia 22 . Recent reports have demonstrated that the non -lactam, but serine modifying inhibitor, avibactam can induce the AmpC -lactamase in Enterobacteriaceae, including E. cloacae and some P. aeruginosa 31 . Thus, we investigated the effects of 2, which has a different mode of action, on -lactamase induction in E. cloacae and P. aeruginosa. As anticipated 22, 31 , with both E. cloacae and P. aeruginosa treatment with a cephalosporin, carbapenem, or clavulanic acid results in an increased production of -lactamases even at 10 g mL -1 ( Figure 3B ). By contrast, avibactam or 2 does not induce -lactamase production within limits of detection with either P. aeruginosa or E. cloacae even at a 50 g mL -1 ( Figure   3 ). (n=2) were also tested; 2, however, did not induce an MIC shift for meropenem in this case.
Conclusions
Boronic acids have been known to inhibit SBLs since the 1970s 32 and have a much longer history as antibaterials (since 1880s) 33 Given the clear differences in spectrum of activities for Vaborbactam and biyclic boronates, with the latter in general appearing better in vitro, there appear to be scope for improving the activity of boronates by extending the rather limited SAR reported to date (at least compared to the enormous studies on -lactam antibiotics / -lactamase inhibitors). The bicyclic boronates studied here and in our prior work closely resemble VNRX-5133 34 ( Figure   1C ), which has not been profiled for MBL coverage. Further studies on the precise binding modes of the boronates to -lactamases and PBPs are of interest, including with respect to increasing their potency versus PBPs and broadening the scope of MBL inhibition (our compounds show only limited inhibitory activity against certain MBLs, including IMP-1, SPM-1, CphA, and L1 1622 . Our preliminary studies suggest that binding to both SBLs and MBLs may involve the sp 2 inhibitor form ( Figure 1B) , again reinforcing the proposed similarity (20, 21) in binding mode of the bicyclic boronates for SBLs and MBLs.
SBL inhibition by clavulanic acid and related -lactams (tazobactam, sulbactam) is proposed to occurs via acy-enzyme fragmentation resulting in inactivation 35 . By contrast, avibactam, inhibits SBLs via reversible covalent binding 35 . As revealed by crystallography, the binding modes of bicyclic boronates, resemble those of intermediates an route to the acyl-enzyme complexes formed with -lactam antibiotics. The boronate inhibitors also exist as an equilibrium between sp 2 /sp 3 states. Thus, it is unclear to what extent borontes will mirrorlactams in terms of their -lactamase inducing capacity. Our results show that 2 does not induce -lactamase production within detection limits in the tested organisms at up to 50 g mL -1 . By contrast, avibactam induces -lactamase production in some P. aeruginosa but not in E. cloacae 31 . The lack of induced -lactamase production by 2, and potentially other boronates, may in part reflect the good clinical coverage observed with co-dosing of 2 with meropenem, which clearly increases the meropenem susceptibility against MBL-positive Enterobacteriaceae. Further structure activity relationship work on the ability of -lactamases inhibitor templates to induce b-lactamases are thus of interest.
